Media Advisory: Dr. Heinrich Roder, Biodesix CTO, To Speak At Precision Medicine World Conference
WHAT: Dr. Heinrich Roder, Biodesix’ CTO, will speak on “Applied Machine Learning for Immuno-Oncology Diagnostics” in the “AI and Data Science Showcase” track at the Precision Medicine World Conference (PMWC) in Mountain View, CA.
WHO: Heinrich Roder is a company founder and author or co-author of more than 100 publications and talks spanning the fields of theoretical physics, computational sciences, and molecular diagnostics. A Rhodes Scholar, he earned his DPhil in Theoretical Physics from the University of Oxford and has held positions at the Universities of Hanover and Bayreuth and at Los Alamos National Laboratory. He is a founder of Biodesix. Serving as CTO, he leads the work of the Research team on sensitive, high-throughput MALDI-ToF mass spectrometry profiling of blood-based samples and the development of molecular diagnostic tests using a machine learning platform incorporating elements of deep learning.
WHEN/WHERE: Monday, January 22nd, 10:30AM PST, at the Computer History Museum, 1401 N. Shoreline Blvd, Mountain View, CA.
Biodesix® is a molecular diagnostics company advancing the development of innovative blood tests in oncology to enable precision medicine. Biodesix discovers, develops and commercializes multivariate protein and genomic diagnostic blood tests, including the GeneStrat® and VeriStrat® tests, that deliver results within 72 hours. The company is changing the standard of care by providing physicians with diagnostic tests for better therapeutic guidance, more accurate prognosis and enhanced disease monitoring to improve patient outcomes. At the forefront of precision medicine, Biodesix is developing new blood tests to identify patients who may benefit from immunotherapies. In addition to developing novel diagnostics independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics for use with therapeutic agents.